Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Geron Corporation (GERN : NSDQ)

• Company Description    Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis. Number of Employees: 258

• Price / Volume Information    Yesterday's Closing Price: $1.54 Daily Weekly Monthly 20 Day Moving Average: 19,548,564 shares Shares Outstanding: 640.54 (millions) Market Capitalization: $986.44 (millions) Beta: 0.58 52 Week High: $2.01 52 Week Low: $1.04 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -12.99% -9.60% 12 Week 12.41% 17.96% Year To Date 16.67% 21.36%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 919 EAST HILLSDALE BOULEVARD SUITE 250 - FOSTER CITY,CA 94404 USA ph: 650-473-7700 fax: 650-473-7750 investor@geron.com http://www.geron.com

• General Corporate Information    Officers HAROUT SEMERJIAN - President; Chief Executive Officer ELIZABETH G. O'FARRELL - Chairman of the Board MICHELLE ROBERTSON - Executive Vice President; Finance; Chief Financial DAWN C. BIR - Director ROBERT J. SPIEGEL - Director Peer Information Geron Corporation (CORR.) Geron Corporation (RSPI) Geron Corporation (CGXP) Geron Corporation (BGEN) Geron Corporation (GTBP) Geron Corporation (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 374163103 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/25 Next Expected EPS Date: 05/06/26 Share - Related Items Shares Outstanding: 640.54 Most Recent Split Date: (:1) Beta: 0.58 Market Capitalization: $986.44 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.03 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.05 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/06/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.35 Price/Cash Flow: - Price / Sales: 5.36 EPS Growth vs. Year Ago Period: 25.00% vs. Previous Quarter: 0.00% Sales Growth vs. Year Ago Period: 1.00% vs. Previous Quarter: 1.67% ROE 12/31/25 - -28.86 09/30/25 - -29.63 06/30/25 - -31.37 ROA 12/31/25 - -12.83 09/30/25 - -13.74 06/30/25 - -16.01 Current Ratio 12/31/25 - 4.66 09/30/25 - 5.96 06/30/25 - 7.87 Quick Ratio 12/31/25 - 3.62 09/30/25 - 4.87 06/30/25 - 6.79 Operating Margin 12/31/25 - -39.33 09/30/25 - -42.68 06/30/25 - -52.48 Net Margin 12/31/25 - -46.65 09/30/25 - -43.61 06/30/25 - -53.52 Pre-Tax Margin 12/31/25 - -45.41 09/30/25 - -43.61 06/30/25 - -53.52 Book Value 12/31/25 - 0.35 09/30/25 - 0.39 06/30/25 - 0.41 Inventory Turnover 12/31/25 - 0.06 09/30/25 - 0.07 06/30/25 - 0.08 Debt-to-Equity 12/31/25 - 0.53 09/30/25 - 0.48 06/30/25 - 0.46 Debt-to-Capital 12/31/25 - 34.61 09/30/25 - 32.41 06/30/25 - 31.44

Powered by Zacks Investment Research ©